Key Events This Week
May 4: Bearish technical shift noted amid mixed momentum signals
May 5-7: Consecutive strong price gains with rising volumes
May 8: Mixed quarterly results reported, stock closes lower
Jun 19, 03:30 PM
BSE+NSE Vol: 1.04 lacs

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 June 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price retreating 3.42% on 10 June 2026 to close at ₹30.78, down from the previous close of ₹31.87.
Read full news article
Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a modest daily price increase of 1.30%, the stock’s technical indicators reveal a nuanced momentum change, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.
Read full news article
Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
May 4: Bearish technical shift noted amid mixed momentum signals
May 5-7: Consecutive strong price gains with rising volumes
May 8: Mixed quarterly results reported, stock closes lower
Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending March 2026 reveal significant operational challenges. The company's net sales experienced a dramatic decline of approximately 83.85% quarter-on-quarter, dropping to ₹6.32 crores from ₹39.13 crores in the previous quarter. This steep fall raises concerns about revenue recognition practices and suggests potential volatility in the company's operational performance. In terms of profitability, Shukra Pharmaceuticals reported a net loss of ₹1.72 crores for the quarter, which reflects a substantial decline compared to the previous quarter's profit. The operating margin also contracted sharply to 11.08%, down from an exceptionally high 69.33% in the prior quarter. This compression in margins indicates a significant shift in the company's cost structure or product mix, which may have been influenced by pricing pressures or changes in dema...
Read full news articleAppointment and Resignation of Company Secretary & Compliance Officer
Newspaper Publication pertaining to EGM to be held on 6th July 2026
Notice of EGM to be held on 6th July 2026
No Upcoming Board Meetings
Shukra Pharmaceuticals Ltd has declared 1% dividend, ex-date: 18 Sep 25
Shukra Pharmaceuticals Ltd has announced 1:10 stock split, ex-date: 21 Mar 25
Shukra Pharmaceuticals Ltd has announced 3:1 bonus issue, ex-date: 19 Apr 24
Shukra Pharmaceuticals Ltd has announced 6:1 rights issue, ex-date: 02 Feb 23